MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer



MedicineWorld.Org - Cancer-Breast Cancer-chemotherapy drug combinations used in breast cancer
Your gateway to information on chemotherapy drug combinations used in breast cancer

chemotherapy drug combinations used in breast cancer: resources

chemotherapy drug combinations used in breast cancer          

             arcgba.gif
  Commonly Used Chemotherapy combinations
  • AC (Combination of Doxorubicin and Cyclophosphamide
  • CMF (Combination of Cyclophosphamide, Methotrexate and Flurouracil)
  • AC --> T (Adriamycin cyclophosphamide followed by Paclitaxel. Every three weeks regimen)
  • Dose Dense AC --> T (same as above but given every two weeks with growth factor support instead of every three weeks)
  • CAF (Cyclophosphamide, Adriamycin, and fluorouracil)
  • ATC (Doxorubicin, Cyclophosphamide, and Taxol)
  • FEC (Fluorouracil Epirubicin, and Cyclophosphamide)
  • Carboplatin and Paclitaxel (with or without herceptin)
  • AC followed by CMF
  • Doxorubicin followed by CMF
  Less Common Chemotherapy Regimens
  • MV: Mitomycin and Vinblastine
  • TA : Docetaxel and Adriamycin
  • 2M: Mitoxantrone and Methotrexate



  •                     ribbon
 
Breast cancer treatment

 
BREAST CANCER MAIN PAGE
Home| Breast cancer news | Common terms| Breast cancer treatment|Treatment by stage| Surgical treatment|Chemotherapy|Chemo drugs| Doxorubicin| Cyclophosphamide| Methotrexate| Hormonal therapy| Radiation therapy| Monoclonal therapy| High dose chemotherapy|Recurrent breast cancer|Bisphosphonates |Pregnancy and breast cancer |Risk factors |Risk details |My risk |Comprehensive |Breast cancer statistics |African Americans |Ashkenazi |Asians |Hispanic |Men |Native Americans |Older women |Younger women |Pregnant women |BRCA
 


Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.